A Phase 3, Prospective, Double Blinded, Randomized Controlled Trial of the Micronized dHACM Injection as Compared to Saline Placebo Injection in the Treatment of Achilles Tendonitis

Trial Profile

A Phase 3, Prospective, Double Blinded, Randomized Controlled Trial of the Micronized dHACM Injection as Compared to Saline Placebo Injection in the Treatment of Achilles Tendonitis

Planning
Phase of Trial: Phase III

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs DHACM (Primary)
  • Indications Pain
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 08 Aug 2017 New trial record
    • 05 Aug 2017 The Company expects patient enrollment to commence in the next few months, according to a MiMedx media release. According to a company media release, MiMedx plans to submit a Biologic License Application (BLA) to the FDA for tendonitis after completion of the Plantar Fasciitis phase 3 trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top